Willenbacher W, Basara N, Blau I W, Fauser A A, Kiehl M G
Clinic for Haematology/Oncology, BMT Programme, Dr Ottmar-Kohler-Str 2, 55743 Idar-Oberstein, Germany.
Br J Haematol. 2001 Mar;112(3):820-3. doi: 10.1046/j.1365-2141.2001.02582.x.
Competitive inhibition of interleukin 2-dependent lymphocytes by daclizumab demonstrates some beneficial effects in the treatment of graft-versus-host disease (GVHD). Sixteen patients with steroid refractory GVHD received daclizumab (1 mg/kg BW) on d 1, 2 (-5), 7, 14 and 21. Twelve patients suffered from grade III-IV acute GVHD and four patients from extensive chronic GVHD. Responses were observed in nine patients (six acute, three chronic GVHD). Fourteen out of 16 patients acquired infections during daclizumab treatment and three deaths were infection related. Daclizumab demonstrates limited activity and is associated with an increased incidence of infectious complications.
达利珠单抗对白细胞介素2依赖性淋巴细胞的竞争性抑制作用在移植物抗宿主病（GVHD）治疗中显示出一些有益效果。16例对类固醇难治的GVHD患者在第1、2（-5）、7、14和21天接受了达利珠单抗（1mg/kg体重）治疗。12例患者患有III-IV级急性GVHD，4例患者患有广泛性慢性GVHD。9例患者（6例急性，3例慢性GVHD）出现了反应。16例患者中有14例在达利珠单抗治疗期间发生感染，3例死亡与感染相关。达利珠单抗显示出有限的活性，并与感染并发症发生率增加有关。
